Microsoft closes the first half of 2026 with a familiar contradiction: options traders have turned sharply defensive again, even as the stock nudges higher and analysts sit 50% above the current price.
The options read is the most interesting data point this week. The put/call ratio jumped to 0.44 on June 30 — more than three standard deviations above its 20-day mean of 0.35. That z-score of 3.16 is essentially identical to the spike flagged in the June 24 trader note, when the ratio hit 0.43 on June 23. Both episodes sit at the extreme end of the year's range, the 52-week high being 0.85. Two three-sigma PCR spikes within a week of each other is not coincidence; it points to persistent demand for downside protection ahead of the July 30 earnings date. The stock closed Tuesday at $373.02, up 1.2% on the day but still down 0.2% on the week and a material 17% over the past month.
The lending market tells a completely different story — and the contrast is worth naming. Short interest is negligible at 1.27% of free float, and borrow conditions are about as relaxed as they get. Cost to borrow has dropped sharply to 0.12%, roughly half its level from earlier in the week and well below the mid-June readings near 0.45%. Availability is essentially uncapped — billions of shares remain lendable against a short position of under 100 million. Short interest itself has risen about 3% over the past week, nudging from roughly 91 million to 94 million shares, but at this absolute level that move is statistical noise, not a directional signal. The borrow market is not the story here.
The Street remains firmly bullish, though a valuation re-rating is already underway. The consensus price target of $561 implies 50%-plus upside from where the stock trades now — a gap that has widened through the month-long slide. Most recent analyst activity has been constructive: TD Cowen, Cantor Fitzgerald, and Citizens all reiterated positive ratings in early June, and Wells Fargo raised its target to $650. The only dissent came last week, when Stifel trimmed its Hold target from $415 to $400 — a modest step down, but the only firm to move against the grain in the recent window. The factor picture broadly supports the bullish side: the analyst recommendation score ranks in the 99th percentile, EPS surprise ranks in the 71st, and the ORTEX stock score recently hit a series high of 78.2. The drag is valuation compression — the P/E multiple has contracted about 3.2 points over 30 days to roughly 20x, and the P/B is down nearly a full point. That de-rating reflects the month's price weakness, not a fundamental deterioration. Bulls will note the EV/EBITDA at 12.5x is actually near a recent trough; bears will point to competitive pressure in productivity software and the margin risk from hosting Azure AI agent runtimes in-house.
Among correlated peers, the picture is mixed. GWRE and TTAN both surged more than 10% on the week, while SAP slipped 0.4% and ESTC fell 3.3%. Microsoft's flat week sits in the middle of the peer distribution — neither the laggard nor the leader — which suggests the stock's weakness is more company-specific than sector-wide rotation.
The two-week pattern of recurring PCR spikes that fade and return now sets a clear watch item for the July 30 print: whether options demand for protection persists at elevated levels through earnings, or collapses again as the April 29 and June 23 spikes both eventually did.
See the live data behind this article on ORTEX.
Open MSFT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
